Advanced search
Publication Cover
International Journal of General Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
123
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Prognostic Value of c-MYC Expression in Patients with Peripheral Neuroblastic Tumors

Feng Zhang1 Department of Otolaryngology, Children’s Hospital of Chongqing Medical University, Chongqing, 400014, People’s Republic of China;2 National Clinical Research Center for Child Health and Disorders, Chongqing, 400014, People’s Republic of China;3 Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, 400014, People’s Republic of ChinaView further author information
,
Zhuo Tian4 Department of Geratology, Chongqing General Hospital, Chongqing, 400014, People’s Republic of ChinaView further author information
,
Tinghong Li5 Department of Pathology, Chongqing Medical University, Chongqing, 400016, People’s Republic of China;6 Institute of Neuroscience, Chongqing Medical University, Chongqing, 400016, People’s Republic of China;7 Key Laboratory of Neurobiology, Chongqing Medical University, Chongqing, 400016, People’s Republic of ChinaView further author information
,
Xianjun Hu4 Department of Geratology, Chongqing General Hospital, Chongqing, 400014, People’s Republic of ChinaView further author information
&
Jin Zhu5 Department of Pathology, Chongqing Medical University, Chongqing, 400016, People’s Republic of China;6 Institute of Neuroscience, Chongqing Medical University, Chongqing, 400016, People’s Republic of China;7 Key Laboratory of Neurobiology, Chongqing Medical University, Chongqing, 400016, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 2901-2907 | Published online: 28 Jun 2021

References

  • Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer. 2001;92(9):2451–2461. doi:10.1002/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S
  • Wang H, Mejia MC, Gonzalez SJ, Zoorob RJ, Chai W, Du XL. Cancer incidence and survival trends among infants in the United States from 1975 to 2014. Pediatr Blood Cancer. 2021;68(4):e28917. doi:10.1002/pbc.28917
  • Shimada H, Ikegaki N. Neuroblastoma pathology and classification for precision prognosis and therapy stratification. Neuroblastoma. 2019. doi:10.1016/B978-0-12-812005-7.00001-1
  • Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349–363. doi:10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y
  • Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411. doi:10.1038/nrc3526
  • Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979–2015. Paediatr Drugs. 2017;19:577–593. doi:10.1007/s40272-017-0251-3
  • Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3:a014415. doi:10.1101/cshperspect.a014415
  • Teshiba R, Kawano S, Wang LL, et al. Age-dependent prognostic effect by mitosis-karyorrhexis index in neuroblastoma: a report from the Children’s Oncology Group. Pediatr Dev Pathol. 2014;17:441–449. doi:10.2350/14-06-1505-OA.1
  • Wang LL, Teshiba R, Ikegaki N, et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study. Br J Cancer. 2015;113:57–63. doi:10.1038/bjc.2015.188
  • Wang LL, Suganuma R, Ikegaki N, et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children’s Oncology Group. Cancer. 2013;119:3718–3726. doi:10.1002/cncr.28251
  • Moreno L, Rubie H, Varo A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European Phase II clinical trials. Pediatr Blood Cancer. 2017;64(1):25–31. doi:10.1002/pbc.26192
  • Pajic M, Norris MD, Cohn SL, Haber M. The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Lett. 2005;228(1–2):241–246. doi:10.1016/j.canlet.2005.01.060
  • Tomolonis JA, Agarwal S, Shohet JM. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development. Cell Tissue Res. 2018;372(2):245–262. doi:10.1007/s00441-017-2747-0
  • Salazar BM, Balczewski EA, Ung CY, Zhu S. Neuroblastoma, a paradigm for big data science in pediatric oncology. Int J Mol Sci. 2016;18(1):37. doi:10.3390/ijms18010037
  • Suganuma R, Wang LL, Sano H, et al. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children’s Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013;60(3):363–370. doi:10.1002/pbc.24238
  • Ambros IM, Hata J, Joshi VV, et al. Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer. 2002;94(5):1574–1583. doi:10.1002/cncr.10359
  • Mina M, Boldrini R, Citti A, et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology. 2015;4(9):e1019981. doi:10.1080/2162402X.2015.1019981

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.